NCT03611946View on ClinicalTrials.gov

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Zika Virus
Interventions
BIOLOGICAL

Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)

Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection

BIOLOGICAL

Single dose of placebo via subcutaneous injection (0.5ml).

Administered by subcutaneous injection.

BIOLOGICAL

Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)

Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.

Trial Locations (2)

21202

Johns Hopkins University, Bloomberg School of Public Health, Baltimore

05401

University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03611946 - Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults | Biotech Hunter | Biotech Hunter